Pfizer Inc Quick Ratio (PFE) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Pfizer Inc  (NYSE: PFE)

Pfizer Inc's Quick Ratio

PFE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Pfizer Inc's Cash & cash equivalent grew by 59.7 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Pfizer Inc's Quick Ratio to 0.64, Quick Ratio remained below Pfizer Inc average.

Within Major Pharmaceutical Preparations industry 381 other companies have achieved higher Quick Ratio than Pfizer Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 631 to 2226.

Explain Quick Ratio?
How much Cash & cash equivalents PFE´s has?
What are PFE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PFE Quick Ratio (Jun 28 2026)
Q2		 (Mar 29 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 28 2025)
Q3		 (Jun 29 2025)
Q2
Y / Y Current Liabilities Change -13.47 % -5.77 % -13.98 % -15.31 % -13.9 %
Y / Y Cash & cash equivalent Change 57.6 % -24.5 % -26.85 % 50.56 % 86.61 %
Quick Ratio MRQ 0.64 0.38 0.63 0.41 0.35
PFE's Total Ranking # 2226 # 631 # 1750 # 619 # 1512
Seq. Current Liabilities Change -4.96 % -7.13 % 1.06 % -3 % 3.5 %
Seq. Cash & cash equivalent Change 59.7 % -44.25 % 56.53 % 13.1 % -23.49 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 382
Healthcare Sector # 703
Overall Market # 2226


Quick Ratio Statistics
High Average Low
2.19 0.84 0.16
(June 30. 2009)   (Jun 30 2024)




Financial Statements
Pfizer Inc's Current Liabilities $ 32,646 Millions Visit PFE's Balance sheet
Pfizer Inc's Cash & cash equivalent $ 20,881 Millions Visit PFE's Balance sheet
Source of PFE's Sales Visit PFE's Sales by Geography


Cumulative Pfizer Inc's Quick Ratio

PFE's Quick Ratio for the trailling 12 Months

PFE Quick Ratio

 (Jun 28 2026)
12 Months		 (Mar 29 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 28 2025)
12 Months		 (Jun 29 2025)
12 Months
Y / Y Current Liabilities TTM Growth -12.35 % -12.51 % -12.06 % -12.27 % -0.38 %
Y / Y Cash & cash equivalent TTM Growth -0.26 % -2.51 % 13.04 % 67.33 % -9.96 %
Quick Ratio TTM 0.51 0.44 0.47 0.5 0.45
Total Ranking TTM # 4085 # 3173 # 2476 # 1285 # 3162
Seq. Current Liabilities TTM Growth -3.49 % -1.42 % -3.91 % -4.12 % -3.66 %
Seq. Cash & cash equivalent TTM Growth 11.78 % -6.15 % -11.09 % 6.93 % 9.26 %

Quick ratio ranking by company, industry and sector >> Back to PFE Financial Strength Comparisons >> Go to Compare PFE Quick Ratio to its Competitors

On the trailing twelve months basis PFE Cash & cash equivalent soared by 57.6 % in Q2 2026 year on year, while Current Liabilities decreased to $32,646 millions, this led to increase in in Pfizer Inc's Quick Ratio to 0.51, Quick Ratio remained below PFE average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Pfizer Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3173 to 4085.

Explain Quick Ratio?
How much Cash & cash equivalents PFE´s has?
What are PFE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 906
Within the Market # 4085


trailing twelve months Quick Ratio Statistics
High Average Low
1.59 0.85 0.24
(June 30. 2009)   (Sep 29 2024)




Companies with similar Quick Ratio in the quarter ending Jun 28 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 28 2026 MRQ Cash & cash equivalentJun 28 2026 MRQ Current Liabilities
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions
Mallinckrodt Plc  1.63 $ 1,075.800  Millions$ 660.600  Millions
Macrogenics Inc   1.59 $ 173.305  Millions$ 108.815  Millions
Fibrobiologics Inc   1.59 $ 3.515  Millions$ 2.213  Millions
Sarepta Therapeutics Inc   1.57 $ 788.489  Millions$ 502.908  Millions
Revium Rx.  1.55 $ 1.506  Millions$ 0.971  Millions
Liquidia Corporation  1.50 $ 284.181  Millions$ 189.298  Millions
Greenwich Lifesciences Inc   1.50 $ 8.876  Millions$ 5.923  Millions
Arcutis Biotherapeutics Inc   1.49 $ 238.552  Millions$ 160.340  Millions
Mirum Pharmaceuticals Inc   1.48 $ 330.728  Millions$ 222.788  Millions
Regeneron Pharmaceuticals Inc   1.45 $ 7,994.600  Millions$ 5,530.600  Millions
Imunon Inc   1.44 $ 6.900  Millions$ 4.779  Millions
Zai Lab Limited  1.44 $ 617.522  Millions$ 428.584  Millions
Mannkind Corporation  1.44 $ 205.271  Millions$ 142.898  Millions
Kyntra Bio Inc   1.41 $ 50.644  Millions$ 36.040  Millions
Medicus Pharma Ltd   1.40 $ 15.174  Millions$ 10.841  Millions
Aurinia Pharmaceuticals Inc   1.39 $ 179.732  Millions$ 129.084  Millions
Omeros Corporation  1.39 $ 131.953  Millions$ 94.963  Millions
Avenue Therapeutics Inc   1.38 $ 1.942  Millions$ 1.407  Millions
Royalty Pharma Plc  1.33 $ 836.986  Millions$ 630.928  Millions
Cormedix Inc   1.31 $ 256.692  Millions$ 196.535  Millions
Transcode Therapeutics Inc   1.30 $ 8.383  Millions$ 6.430  Millions
Elite Pharmaceuticals Inc   1.28 $ 39.032  Millions$ 30.442  Millions

Date modified: 2026-09-12T06:19:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.